Related references
Note: Only part of the references are listed.Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer
Chia-Chi Hsu et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
B. C. Cho et al.
ANNALS OF ONCOLOGY (2020)
JNJ-61186372, an EGFRcMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC)
Jiyeon Yun et al.
CANCER RESEARCH (2020)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
S. Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR plus Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
J. Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Natalie M. Andrews Wright et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer
Jiyeon Yun et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H
Matthew A. Gubens et al.
LUNG CANCER (2019)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn et al.
LANCET ONCOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression
Jai-Nien Tung et al.
ONCOTARGET (2018)
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
David Waterhouse et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Zheng-Hai Tang et al.
CANCER LETTERS (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
Shengwu Liu et al.
CLINICAL CANCER RESEARCH (2018)
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P. Kalemkerian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
A. Lisberg et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Sanjay Popat
NEW ENGLAND JOURNAL OF MEDICINE (2018)
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
Pang-Dian Fan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer
Tae-Ok Kim et al.
THORACIC CANCER (2018)
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer
Yasuo Oshima et al.
JAMA ONCOLOGY (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non-small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.
Morihito Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
Shan Su et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells
Matteo Turetta et al.
CANCERS (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
G. Riely et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
K. Nakagawa et al.
ANNALS OF ONCOLOGY (2017)
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
B.B.Y. Ma et al.
ANNALS OF ONCOLOGY (2017)
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
L. Castagnoli et al.
ONCOGENE (2017)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Silvia La Monica et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
Yi Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer
Suzanne Jenkins et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
Ross A. Soo et al.
LUNG CANCER (2017)
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
Franciele H. Knebel et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Myung-Ju Ahn et al.
LANCET RESPIRATORY MEDICINE (2017)
1228PDEPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT RESPONSE IN ADVANCED NON-SMALL CELL LUNG CANCER WITH G719X/L861Q/S768I MUTATIONS
C. Chiu et al.
ANNALS OF ONCOLOGY (2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
K. Haratani et al.
ANNALS OF ONCOLOGY (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Tilak K. Sundaresan et al.
CLINICAL CANCER RESEARCH (2016)
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
M. Jamal-Hanjani et al.
ANNALS OF ONCOLOGY (2016)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Sandra Ortiz-Cuaran et al.
CLINICAL CANCER RESEARCH (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
J. Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC
D. L. Gibbons et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
M. -J. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Lecia V. Sequist et al.
JAMA ONCOLOGY (2016)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Cheng Lin et al.
CLINICAL LUNG CANCER (2015)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Pretreated Non-Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Petra Hoffknecht et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean-Charles Soria et al.
LANCET ONCOLOGY (2015)
EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Niina Laurila et al.
MEDICAL ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska et al.
CANCER DISCOVERY (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
Analysis of intratumor heterogeneity unravels lung cancer evolution
Elza C. de Bruin et al.
MOLECULAR & CELLULAR ONCOLOGY (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
S. J. Antonia et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
Christos Chouaid et al.
LUNG CANCER (2014)
Immunotherapy in the treatment of non-small cell lung cancer
Raghav Sundar et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)
Pasi A. Janne et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A. Akbay et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Federica Moschella et al.
THYMOSINS IN HEALTH AND DISEASE (2010)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
H Shigematsu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The epidermal growth factor receptor family
LA Bazley et al.
ENDOCRINE-RELATED CANCER (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)